Bookmark

Add to MyYahoo RSS

ImmunoGen News

News on ImmunoGen (Ticker: IMGN) continually updated from thousands of sources around the net.

15 min ago | Freshnews

ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results

ImmunoGen, Inc . , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, ImmunoGen

4 hrs ago | Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Peluso, 42, is Chief Executive Officer of Gil... )--The GEO Group, Inc. will release its first quarter 2014 financial results on Tuesday, April 29, 2014 before the market opens.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Apparel, Nike, Footwear, Retail, Zale, Jewelry

Wed Apr 16, 2014

MarketNewsVideo

Wednesday Sector Leaders: Biotechnology, Rubber & Plastics

In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 2%.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, ImmunoGen, Business News, Video

Forbes.com

Wednesday's ETF Movers: FBT, GDX

In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 2.6% on the day.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, InterMune, Financial Markets

AmericanBankingNews.com

Immunogen Rating Reiterated by Canaccord Genuity

's stock had its "buy" rating reaffirmed by investment analysts at Canaccord Genuity in a note issued to investors on Wednesday, American Banking and Market News reports.

Comment?

Related Topix: Biotech, Medicine, ImmunoGen, Healthcare Industry

Thu Apr 10, 2014

Sys-Con Media

Pre-Market Scans on Top Gainers -- Research on Athlon Energy,...

The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets

SchaeffersResearch.com

Stocks to Watch Thursday: VIVUS, Inc., Zillow Inc, and ImmunoGen, Inc.

Interestingly, short-term call open interest has almost doubled since March 24, while put open interest climbed less than 1%.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, VIVUS, Financial Markets, Day Trading, Personal Finance

Tue Apr 08, 2014

Business Wire

ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853

The data were presented at the American Association for Cancer Research Annual Meeting in San Diego, CA.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, ImmunoGen

Mon Apr 07, 2014

AmericanBankingNews.com

Immunogen Rating Increased to Outperform at Zacks

The firm currently has a $15.90 target price on the stock. Zacks 's price objective suggests a potential upside of 19.64% from the company's previous close.

Comment?

Related Topix: Biotech, Medicine, ImmunoGen, Healthcare Industry

Tue Apr 01, 2014

Business Wire

SAGE Therapeutics Appoints Howard H. Pien to the Companya s Board of Directors

"Howard is a seasoned industry leader with deep biopharmaceutical expertise, especially in guiding companies as they expand and evolve from research and development to clinical stage," said Jeff Jonas, M.D., chief executive officer of SAGE Therapeutics.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Medarex

Fri Mar 28, 2014

Hispanic Business

Friday's ETF Movers: GXC, FBT

Components of that ETF showing particular strength include shares of , up about 7.8% on the day.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Thu Mar 20, 2014

Hispanic Business

ImmunoGen Schedules Presentations by Company Scientists at Upcoming AACR Annual Meeting

"They also include highly encouraging preclinical findings with both our IMGN289 and IMGN853 compounds, as well as data on some of the more recent additions to our ADC technology portfolio."

Comment?

Related Topix: Biotech, Medicine, ImmunoGen, Healthcare Industry, Pharmacology

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••